General information, page-90

Hi Shellbell, I think that Cellprime M the manufacturing component at this stage would be being looked at by potential partners. Cellpryme A the Adjuvant Component as l understand it is still not quite ready for the clinic, but if Cellpryme A shows promise that will be another string to our bow. But as l understand it nearly the total focus is on the PTX100 study as it should be, if the patient results are similar in the PTX100 phase 2 study as the PTX100 phase 1 study and our safety is on track as expected we are destined for a licensing agreement and commercialisation. Just my thoughts Logan